At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 500 enrolled
Drug / intervention
Chantix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Advancing Tobacco Use Treatment for African American Smokers
In Brief
A Phase 4 clinical trial evaluating Chantix and Placebo for Smoking Cessation. Completed, enrolled 500 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine whether or not providing Chantix (varenicline) will help African American smokers quit smoking.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartJul 2015
Primary CompletionJul 2018
TodayJul 2026
First PostedFeb 10, 2015
Enrollment StartJul 29, 2015
Primary CompletionJul 12, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.4 years ago
Interventions
Chantixdrug
A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
Placebodrug
Health education counseling will be provided to all participants.